Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Trial Profile

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2016 Planned End Date changed from 1 Mar 2020 to 1 Jul 2017.
    • 01 Aug 2016 Status changed from recruiting to discontinued.
    • 30 Mar 2015 Planned End Date changed from 1 Dec 2016 to 1 Mar 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top